RT Journal Article
SR Electronic
T1 Repeatability and sensitivity to change of non-invasive end points in PAH: the RESPIRE study
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 1032
OP 1035
DO 10.1136/thoraxjnl-2020-216078
VO 76
IS 10
A1 Andrew J Swift
A1 Frederick Wilson
A1 Marcella Cogliano
A1 Lindsay Kendall
A1 Faisal Alandejani
A1 Samer Alabed
A1 Paul Hughes
A1 Yousef Shahin
A1 Laura Saunders
A1 Charlotte Oram
A1 David Capener
A1 Alex Rothman
A1 Pankaj Garg
A1 Christopher Johns
A1 Matthew Austin
A1 Alistair Macdonald
A1 Jo Pickworth
A1 Peter Hickey
A1 Robin Condliffe
A1 Anthony Cahn
A1 Allan Lawrie
A1 Jim M Wild
A1 David G Kiely
YR 2021
UL http://thorax.bmj.com/content/76/10/1032.abstract
AB End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test–retest repeatability was assessed using the intraclass correlation coefficient and treatment effect size using Cohen’s d statistic. Intraclass correlation coefficients demonstrated excellent repeatability for MRI, 6 min walk test and log to base 10 N-terminal pro-brain natriuretic peptide (log10NT-proBNP). The treatment effect size for MRI-derived right ventricular ejection fraction was large (Cohen’s d 0.81), whereas the effect size for the 6 min walk test (Cohen’s d 0.22) and log10NT-proBNP (Cohen’s d 0.20) were fair. This study supports further evaluation of MRI as a non-invasive end point for clinical assessment and PAH therapy trials.Trial registration number NCT03841344.